Cargando…

SARS-CoV-2 elicits robust adaptive immune responses regardless of disease severity

BACKGROUND: The SARS-CoV-2 pandemic currently prevails worldwide. To understand the immunological signature of SARS-CoV-2 infections and aid the search and evaluation of new treatment modalities and vaccines, comprehensive characterization of adaptive immune responses towards SARS-CoV-2 is needed. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nielsen, Stine SF, Vibholm, Line K, Monrad, Ida, Olesen, Rikke, Frattari, Giacomo S, Pahus, Marie H, Højen, Jesper F, Gunst, Jesper D, Erikstrup, Christian, Holleufer, Andreas, Hartmann, Rune, Østergaard, Lars, Søgaard, Ole S, Schleimann, Mariane H, Tolstrup, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176920/ https://www.ncbi.nlm.nih.gov/pubmed/34098342 http://dx.doi.org/10.1016/j.ebiom.2021.103410

Ejemplares similares

SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses
por: Vibholm, Line K, et al.
Publicado: (2021)

Redirector of Vaccine-induced Effector Responses (RoVER) for specific killing of cellular targets
por: Konrad, Christina V., et al.
Publicado: (2023)

Single cell analysis reveals a subset of cytotoxic-like plasmacytoid dendritic cells in people with HIV-1
por: Cham, Lamin B., et al.
Publicado: (2023)

CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy
por: Lende, Stine Sofie Frank, et al.
Publicado: (2022)

Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients
por: Cham, Lamin B., et al.
Publicado: (2021)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution
por: Monrad, Ida, et al.
Publicado: (2021)

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
por: Gunst, Jesper D., et al.
Publicado: (2023)

Long-term humoral and cellular immunity after primary SARS-CoV-2 infection: a 20-month longitudinal study
por: Hvidt, Astrid Korning, et al.
Publicado: (2023)

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8(+) T cell immunity
por: Rosás-Umbert, Miriam, et al.
Publicado: (2022)

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses
por: Brinkmann, Christel Rothe, et al.
Publicado: (2018)

Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
por: Gunst, Jesper D., et al.
Publicado: (2021)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
por: Krarup, Astrid Raaby, et al.
Publicado: (2017)

Immune checkpoints and the HIV-1 reservoir: proceed with caution
por: Olesen, Rikke, et al.
Publicado: (2016)

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes
por: Schleimann, Mariane H., et al.
Publicado: (2019)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

Comparable human reconstitution following Cesium-137 versus X-ray irradiation preconditioning in immunodeficient NOG mice
por: Andersen, Anna Halling Folkmar, et al.
Publicado: (2020)

HSV-1-induced chemokine expression via IFI16-dependent and IFI16-independent pathways in human monocyte-derived macrophages
por: Søby, Stine, et al.
Publicado: (2012)

The Impact of B-Cell Perturbations on Pneumococcal Conjugate Vaccine Response in HIV-Infected Adults
por: Johannesson, Thomas G., et al.
Publicado: (2012)

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Immunomodulation with IL-7 and IL-15 in HIV-1 infection
por: Gunst, Jesper D., et al.
Publicado: (2023)

Persistent Symptoms in Patients Recovering From COVID-19 in Denmark
por: Leth, Steffen, et al.
Publicado: (2021)

The development of a questionnaire to assess leisure time screen-based media use and its proximal correlates in children (SCREENS-Q)
por: Klakk, Heidi, et al.
Publicado: (2020)

Prognosis of ruptured abdominal aortic aneurysms in Denmark from 1994–2008
por: Lindholt, Jes S, et al.
Publicado: (2012)

Cost effectiveness of abdominal aortic aneurysm screening and rescreening in men in a modern context: evaluation of a hypothetical cohort using a decision analytical model
por: Søgaard, Rikke, et al.
Publicado: (2012)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

Acute Appendicitis as the Initial Clinical Presentation of Primary HIV-1 Infection
por: Schleimann, Mariane H, et al.
Publicado: (2018)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Characteristics of a Danish Post-COVID Cohort Referred for Examination due to Persistent Symptoms Six Months after Mild Acute COVID-19
por: Agergaard, Jane, et al.
Publicado: (2022)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

Editorial: COVID-19: From bedside to follow-up
por: Gunst, Jesper Damsgaard, et al.
Publicado: (2023)

Long-Term Symptoms among Hospitalized COVID-19 Patients 48 Weeks after Discharge—A Prospective Cohort Study
por: Mølhave, Martin, et al.
Publicado: (2021)

Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease
por: Amo-Aparicio, Jesus, et al.
Publicado: (2023)

Characterization of HIV-1 Infection and Innate Sensing in Different Types of Primary Human Monocyte-Derived Macrophages
por: Diget, Elisabeth A., et al.
Publicado: (2013)

High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial
por: Hansen, Kristoffer S., et al.
Publicado: (2022)

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials
por: Rasmussen, Thomas A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_39k8ifuil56q71nc3ed2ccj5n9